lbs-008
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Nov 15, 2018 (NCT03735810)
Timeline
Indications
Mechanism of action
- Plasma retinol-binding proteinMODULATOR
RBP4 modulator
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N1CCc2c(C(=O)N3CCC(c4ccc(F)c(F)c4C(F)(F)F)CC3)n[nH]c2C1- Mol. weight
- 456.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3967849 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06388083 | Phase 2/Phase 3 (Phase 3) | Jul 31, 2024 | Belite Bio, Inc |
| NCT05949593 | Phase 3 | Jul 27, 2023 | Belite Bio, Inc |
| NCT06027346 | Phase 1 | Jul 17, 2023 | Yiling Pharmaceutical Inc. |
| NCT05667688 | Phase 1 | Dec 31, 2022 | Belite Bio, Inc, Nucleus Network Ltd |
| NCT05244304 | Phase 3 | Mar 28, 2022 | Belite Bio, Inc |
| NCT05266014 | Phase 1/Phase 2 (Phase 2) | Mar 12, 2021 | Belite Bio, Inc |
| NCT03735810 | Phase 1 | Nov 15, 2018 | Belite Bio, Inc |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Belite Bio, Inc | For profit | 6 | 6 | 3 | 2018 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2022 |
| Yiling Pharmaceutical Inc. | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1